ICON in Asia

We understand the unique challenges of conducting research in the Asia Pacific region and use our country-specific knowledge to ensure we deliver quality data to our clients on time and within budget.

We operate in eleven countries (Australia, China, India, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand), and have the capability and expertise to conduct clinical trials and development projects on both a local, cross-region and global basis and provide the full range of ICON Services.

At ICON, we use our insight and innovation to drive measurable performance improvements. Our operational capability and therapeutic expertise enable us to deliver value and operational excellence in drug development projects, which translates into constantly exceeding client expectations.

Why Asia Pacific?

A number of factors contribute to Asia Pacific being an excellent location for clinical trials:

• Regulatory bodies are actively encouraging Multi Regional Clinical Trials
• Patient access - Two-thirds of the world’s population live in the region
• Relatively less competition for patients with fewer clinical trials enrolling compared to US & EU
• High prevalence of certain diseases - diabetes, hepatitis B, cardiovascular, chronic  lower respiratory disease, influenza and pneumonia
• Strong presence of academic institutions and high-quality investigators
• ICH-GCP guidelines have been adopted for more than 10 years
• Quality is constantly improving and standards are comparable to western standards
• Significant progress has been made by some key territories to enforce IPP and implement patent laws
• Costs are relatively lower in some countries compared to US and EU